Market Herald logo


Be the first with the news that moves the market
  • Recce Pharmaceuticals has raised nearly $7 million to progress its lead antibiotic that treats blood infections and sepsis
  • The placement issued 26 million shares at a price of 26¢ per share
  • The company is now fully funded for the Australian Therapeutic Goods Administration and the Phase I human clinical study which will determine the safety and dosing of the antibiotic
  • Recce is down 7.94 per cent today and is selling shares for 29¢ apiece

Recce Pharmaceuticals raised nearly $7 million to progress its lead antibiotic, RECCE 327.

The placement was well supported, closing early with a scaled acceptance from existing and new Australian and international investors.

A total of 26 million shares were issued at 26¢ per share and raised $6.76 million.

Proceeds will be used to progress its RECCE 327, treatment of blood infections and sepsis. The antibiotic was supported by the Australian Government’s 43.5 per cent Research and development (R&D) rebate on R&D applicable activities.

The company is now fully funded for the Australian Therapeutic Goods Administration (TGA) Special Access Scheme activities and the Phase I human clinical study to determine safety and dosing.

Chairman Dr John Prendergast is pleased with the strong support from the existing and the new shareholders.

“Demand significantly exceeded the capital raised with our business now well-funded to progress the company’s clinical programs and global commercialisation strategy,” he said.

“Most assuredly, we are delighted by this interest in Recce as we believe it also underscores the intense desire to find innovative approaches that can address the global crisis of multidrug resistant bacteria and their superbug forms,” he added.

The settlement is expected to occur on October 14. New shares issued under the placement are expected to be issued on October 15.

RCE by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.